Skip to main content

Advertisement

Articles

Page 11 of 15

  1. Alzheimer’s disease (AD) is characterized by the formation of senile plaques and neurofibrillary tangles composed of phosphorylated Tau. Several findings suggest that correcting signal dysregulation for Tau ph...

    Authors: Yasuko Kitagishi, Atsuko Nakanishi, Yasunori Ogura and Satoru Matsuda

    Citation: Alzheimer's Research & Therapy 2014 6:35

    Content type: Review

    Published on:

  2. Administration of several cardiovascular drugs has an effect on dementia. We aimed to investigate whether there are differences in the use of cardiovascular medication between different dementia disorders.

    Authors: Pavla Cermakova, Seyed-Mohammad Fereshtehnejad, Kristina Johnell, Bengt Winblad, Maria Eriksdotter and Dorota Religa

    Citation: Alzheimer's Research & Therapy 2014 6:34

    Content type: Research

    Published on:

    The Erratum to this article has been published in Alzheimer's Research & Therapy 2014 6:63

  3. Vascular dementia is the second most common cause of dementia after Alzheimer’s disease (AD). In addition, it is estimated that almost half of all AD patients have significant cerebrovascular disease comorbid ...

    Authors: Tiffany L Sudduth, Erica M Weekman, Holly M Brothers, Kaitlyn Braun and Donna M Wilcock

    Citation: Alzheimer's Research & Therapy 2014 6:32

    Content type: Research

    Published on:

  4. Immunotherapy targeting amyloid-β peptide is under active clinical investigation for treatment of Alzheimer’s disease (AD). Among the hypotheses being investigated for impact on clinical outcome are the prefer...

    Authors: Hadar Feinberg, José W Saldanha, Linnea Diep, Amita Goel, Angela Widom, Geertruida M Veldman, William I Weis, Dale Schenk and Guriqbal S Basi

    Citation: Alzheimer's Research & Therapy 2014 6:31

    Content type: Research

    Published on:

  5. The identification of tau protein as a major constituent of neurofibrillary tangles spurred considerable effort devoted to identifying and validating pathways through which therapeutics may alleviate tau burde...

    Authors: Casey Cook, Jeannette N Stankowski, Yari Carlomagno, Caroline Stetler and Leonard Petrucelli

    Citation: Alzheimer's Research & Therapy 2014 6:29

    Content type: Review

    Published on:

  6. Alzheimer’s disease pathology is closely connected to the processing of the amyloid precursor protein (APP) resulting in the formation of a variety of amyloid-beta (Aβ) peptides. They are found as insoluble ag...

    Authors: Markus P Kummer and Michael T Heneka

    Citation: Alzheimer's Research & Therapy 2014 6:28

    Content type: Review

    Published on:

  7. Lower angiotensin-converting enzyme (ACE) activity could increase the risk of Alzheimer’s disease (AD) as ACE functions to degrade amyloid-β (Aβ). Therefore, we investigated whether ACE protein and activity le...

    Authors: Hadassa M Jochemsen, Charlotte E Teunissen, Emma L Ashby, Wiesje M van der Flier, Ruth E Jones, Mirjam I Geerlings, Philip Scheltens, Patrick G Kehoe and Majon Muller

    Citation: Alzheimer's Research & Therapy 2014 6:27

    Content type: Research

    Published on:

  8. Vaccination against amyloid-β protein (Aβ42) induces high levels of antibody, making it a promising strategy for treating Alzheimer’s disease (AD). One drawback in the past was that clinical trial approval was...

    Authors: Shuang Wang, Yang Yu, Shuang Geng, Dongmei Wang, Li Zhang, Xiaoping Xie, Bing Wu, Chaofan Li, Hanqian Xu, Xiaolin Li, Yanxin Hu, Lianfeng Zhang, Christoph Kaether and Bin Wang

    Citation: Alzheimer's Research & Therapy 2014 6:26

    Content type: Research

    Published on:

  9. The objective was to study whether α-synuclein oligomers are altered in the cerebrospinal fluid (CSF) of patients with dementia, including Parkinson disease with dementia (PDD), dementia with Lewy bodies (DLB)...

    Authors: Oskar Hansson, Sara Hall, Annika Öhrfelt, Henrik Zetterberg, Kaj Blennow, Lennart Minthon, Katarina Nägga, Elisabet Londos, Shiji Varghese, Nour K Majbour, Abdulmonem Al-Hayani and Omar MA El-Agnaf

    Citation: Alzheimer's Research & Therapy 2014 6:25

    Content type: Research

    Published on:

  10. The Alzheimer’s Drug Discovery Foundation’s 14th International Conference on Alzheimer’s Drug Discovery was held on 9 and 10 September in Jersey City, NJ, USA. This annual meeting highlights novel therapeutic ...

    Authors: Lauren G Friedman, Katherine Price, Rachel F Lane, Aaron J Carman, Penny A Dacks, Diana W Shineman and Howard M Fillit

    Citation: Alzheimer's Research & Therapy 2014 6:22

    Content type: Meeting report

    Published on:

  11. Lewy body dementia (LBD) is the second most common neurodegenerative dementia in older adults, yet there remains a delay in diagnosis that limits healthcare providers’ ability to maximize therapeutic outcomes ...

    Authors: Yael R Zweig and James E Galvin

    Citation: Alzheimer's Research & Therapy 2014 6:21

    Content type: Review

    Published on:

  12. Emerging evidence suggests that decreased adult hippocampal neurogenesis represents an early critical event in the course of Alzheimer’s disease (AD). In mice, adult neurogenesis is reduced by knock-in alleles...

    Authors: Keith A Wesnes, Peter Annas, Hans Basun, Chris Edgar and Kaj Blennow

    Citation: Alzheimer's Research & Therapy 2014 6:20

    Content type: Research

    Published on:

  13. In this study, we evaluated the safety and pharmacodynamic effects of the Fc-inactivated anti-β-amyloid (anti-Aβ) monoclonal antibody GSK933776 in patients with mild Alzheimer’s disease and mild cognitive impa...

    Authors: Thomas Leyhe, Niels Andreasen, Monica Simeoni, Arno Reich, Christine AF von Arnim, Xin Tong, Astrid Yeo, Shahid Khan, Amy Loercher, Michelle Chalker, Charles Hottenstein, Henrik Zetterberg, Jan Hilpert and Prafull Mistry

    Citation: Alzheimer's Research & Therapy 2014 6:19

    Content type: Research

    Published on:

  14. This review summarises the findings and applications from neuroimaging studies in dementia with Lewy bodies (DLB), highlighting key differences between DLB and other subtypes of dementia. We also discuss the i...

    Authors: Elijah Mak, Li Su, Guy B Williams and John T O’Brien

    Citation: Alzheimer's Research & Therapy 2014 6:18

    Content type: Review

    Published on:

  15. TMEM106B is a transmembrane glycoprotein of unknown function located within endosome/lysosome compartments expressed ubiquitously in various cell types. Previously, the genome-wide association study (GWAS) ide...

    Authors: Jun-ichi Satoh, Yoshihiro Kino, Natsuki Kawana, Yoji Yamamoto, Tsuyoshi Ishida, Yuko Saito and Kunimasa Arima

    Citation: Alzheimer's Research & Therapy 2014 6:17

    Content type: Research

    Published on:

  16. The symptomatic drugs currently on the market for Alzheimer’s disease (AD) have no effect on disease progression, and this creates a large unmet medical need. The type of drug that has developed most rapidly i...

    Authors: Lars Lannfelt, Christer Möller, Hans Basun, Gunilla Osswald, Dag Sehlin, Andrew Satlin, Veronika Logovinsky and Pär Gellerfors

    Citation: Alzheimer's Research & Therapy 2014 6:16

    Content type: Review

    Published on:

  17. The progressive dementia that is characteristic of Alzheimer’s disease is associated with the accumulation of amyloid-beta (Aβ) peptides in extracellular plaques and within neurons. Aβ peptides are targeted to...

    Authors: Charlotte Simmons, Victoria Ingham, Alun Williams and Clive Bate

    Citation: Alzheimer's Research & Therapy 2014 6:15

    Content type: Research

    Published on:

  18. Many progressive neurodegenerative diseases, including Alzheimer disease, Parkinson disease, Huntington disease, amyotrophic lateral sclerosis, and frontotemporal lobe dementia, are associated with the formati...

    Authors: Faisal Fecto, Y Taylan Esengul and Teepu Siddique

    Citation: Alzheimer's Research & Therapy 2014 6:13

    Content type: Review

    Published on:

  19. “Partners in Dementia Care” (PDC) tested the effectiveness of a care-coordination program integrating healthcare and community services and supporting veterans with dementia and their caregivers. Delivered via...

    Authors: David M Bass, Katherine S Judge, ALynn Snow, Nancy L Wilson, Robert O Morgan, Katie Maslow, Ronda Randazzo, Jennifer A Moye, Germaine L Odenheimer, Elizabeth Archambault, Richard Elbein, Paul Pirraglia, Thomas A Teasdale, Catherine A McCarthy, Wendy J Looman and Mark E Kunik

    Citation: Alzheimer's Research & Therapy 2014 6:9

    Content type: Research

    Published on:

  20. Tau pathology is associated with a number of age-related neurodegenerative disorders. Few treatments have been demonstrated to diminish the impact of tau pathology in mouse models and none are yet effective in...

    Authors: Maj-Linda Selenica, Leif Benner, Steven B Housley, Barbara Manchec, Daniel C Lee, Kevin R Nash, Jay Kalin, Joel A Bergman, Alan Kozikowski, Marcia N Gordon and Dave Morgan

    Citation: Alzheimer's Research & Therapy 2014 6:12

    Content type: Research

    Published on:

  21. The introduction of tau imaging agents such as 18F-THK523 offers new hope for the in vivo assessment of tau deposition in tauopathies such as Alzheimer’s disease (AD), where preliminary 18F-THK523-PET studies hav...

    Authors: Michelle T Fodero-Tavoletti, Shozo Furumoto, Leanne Taylor, Catriona A McLean, Rachel S Mulligan, Ian Birchall, Ryuichi Harada, Colin L Masters, Kazuhiko Yanai, Yukitsuka Kudo, Christopher C Rowe, Nobuyuki Okamura and Victor L Villemagne

    Citation: Alzheimer's Research & Therapy 2014 6:11

    Content type: Research

    Published on:

  22. Sports-related concussions are one of the major causes of mild traumatic brain injury. Although most patients recover completely within days to weeks, those who experience repetitive brain trauma (RBT) may be ...

    Authors: Thomas SC Ng, Alexander P Lin, Inga K Koerte, Ofer Pasternak, Huijun Liao, Sai Merugumala, Sylvain Bouix and Martha E Shenton

    Citation: Alzheimer's Research & Therapy 2014 6:10

    Content type: Review

    Published on:

  23. Alzheimer’s disease (AD) is a devastating neurodegenerative disorder, afflicting more than one-third of people over the age of 85. While many therapies for AD are in late-stage clinical testing, rational drug ...

    Authors: Haakon B Nygaard, Christopher H van Dyck and Stephen M Strittmatter

    Citation: Alzheimer's Research & Therapy 2014 6:8

    Content type: Review

    Published on:

  24. Alzheimer’s disease (AD) is the most common cause of dementia and a major contributor to disability and dependency among older people. AD pathogenesis is associated with the accumulation of amyloid-beta protei...

    Authors: Bengt Winblad, Ana Graf, Marie-Emmanuelle Riviere, Niels Andreasen and J Michael Ryan

    Citation: Alzheimer's Research & Therapy 2014 6:7

    Content type: Review

    Published on:

  25. Cerebrospinal fluid (CSF) amyloid-beta 38 (Aβ38), 40 (Aβ40), 42 (Aβ42) and total tau (T-tau) are finding increasing utility as biomarkers of Alzheimer’s disease (AD). The purpose of this study was to determine...

    Authors: Jamie Toombs, Ross W Paterson, Jonathan M Schott and Henrik Zetterberg

    Citation: Alzheimer's Research & Therapy 2014 6:5

    Content type: Research

    Published on:

  26. Dementia is currently diagnosed based on clinical symptoms and signs, but significant brain damage has already occurred by the time a clinical diagnosis of dementia is made, and it is increasingly recognized t...

    Authors: Galit Weinstein and Sudha Seshadri

    Citation: Alzheimer's Research & Therapy 2014 6:6

    Content type: Review

    Published on:

  27. Chronic traumatic encephalopathy (CTE) is a progressive neurodegenerative disease that occurs in association with repetitive traumatic brain injury experienced in sport and military service. In most instances,...

    Authors: Thor D Stein, Victor E Alvarez and Ann C McKee

    Citation: Alzheimer's Research & Therapy 2014 6:4

    Content type: Review

    Published on:

  28. Perhaps more definitively than any other class of novel Alzheimer’s disease (AD) therapy, pre-clinical studies in mouse models of amyloid β (Aβ) deposition have established the disease-modifying potential of a...

    Authors: Todd E Golde

    Citation: Alzheimer's Research & Therapy 2014 6:3

    Content type: Review

    Published on:

  29. Previous work has demonstrated the efficacy of irradiating tissue with red to infrared light in mitigating cerebral pathology and degeneration in animal models of stroke, traumatic brain injury, parkinsonism a...

    Authors: Sivaraman Purushothuman, Daniel M Johnstone, Charith Nandasena, John Mitrofanis and Jonathan Stone

    Citation: Alzheimer's Research & Therapy 2014 6:2

    Content type: Research

    Published on:

  30. Microtubule-associated protein tau encoded by the MAPT gene binds to microtubules and is important for maintaining neuronal morphology and function. Alternative splicing of MAPT pre-mRNA generates six major tau i...

    Authors: Melissa E Murray, Naomi Kouri, Wen-Lang Lin, Clifford R Jack Jr, Dennis W Dickson and Prashanthi Vemuri

    Citation: Alzheimer's Research & Therapy 2014 6:1

    Content type: Review

    Published on:

  31. Growing evidence suggests that vascular perturbation plays a critical role in the pathogenesis of Alzheimer’s disease (AD). It appears to be a common feature in addition to the classic pathological hallmarks o...

    Authors: Wilfred A Jefferies, Katherine A Price, Kaan E Biron, Franz Fenninger, Cheryl G Pfeifer and Dara L Dickstein

    Citation: Alzheimer's Research & Therapy 2013 5:64

    Content type: Review

    Published on:

  32. The Severe Impairment Battery (SIB) is validated for assessing cognition in patients with severe dementia. The current analysis aimed to further investigate the cognitive efficacy of rivastigmine capsules, as ...

    Authors: Steven Ferris, Stella Karantzoulis, Monique Somogyi and Xiangyi Meng

    Citation: Alzheimer's Research & Therapy 2013 5:63

    Content type: Research

    Published on:

  33. Symptomatic treatments for Alzheimer’s disease should retain a place in the advanced stages of disease since their actions on these symptoms, even if not modifying the course of disease, are critical for impro...

    Authors: Pierre Jean Ousset, Julien Delrieu and Bruno Vellas

    Citation: Alzheimer's Research & Therapy 2013 5:62

    Content type: Debate

    Published on:

  34. γ-Secretase-mediated production of amyloid β from the amyloid precursor protein is recognized as a central player in the neuropathogenesis of Alzheimer’s disease (AD). One of the most peculiar features of this...

    Authors: Nathalie Jurisch-Yaksi and Wim Annaert

    Citation: Alzheimer's Research & Therapy 2013 5:61

    Content type: Review

    Published on:

  35. The oligomer cascade hypothesis, which states that oligomers are the initiating pathologic agents in Alzheimer’s disease, has all but supplanted the amyloid cascade hypothesis, which suggested that fibers were...

    Authors: Eric Y Hayden and David B Teplow

    Citation: Alzheimer's Research & Therapy 2013 5:60

    Content type: Review

    Published on:

  36. The amyloid-β42 (Aβ42) peptide plays a crucial role in the pathogenesis of Alzheimer’s disease (AD), the most common neurodegenerative disorder affecting the elderly. Over the past years, several approaches and c...

    Authors: Sabrina Meister, Iavor Zlatev, Julia Stab, Dominic Docter, Sandra Baches, Roland H Stauber, Mordechai Deutsch, Reinhold Schmidt, Stefan Ropele, Manfred Windisch, Klaus Langer, Sylvia Wagner, Hagen von Briesen, Sascha Weggen and Claus U Pietrzik

    Citation: Alzheimer's Research & Therapy 2013 5:51

    Content type: Research

    Published on:

  37. Souvenaid® containing Fortasyn® Connect is a medical food designed to support synapse synthesis in persons with Alzheimer’s disease (AD). Fortasyn Connect includes precursors (uridine monophosphate; choline; p...

    Authors: Raj C Shah, Patrick J Kamphuis, Sue Leurgans, Sophie H Swinkels, Carl H Sadowsky, Anke Bongers, Stephen A Rappaport, Joseph F Quinn, Rico L Wieggers, Philip Scheltens and David A Bennett

    Citation: Alzheimer's Research & Therapy 2013 5:59

    Content type: Research

    Published on:

  38. Fluid biomarkers improve the diagnostic accuracy in dementia and provide an objective measure potentially useful as a therapeutic response in clinical trials. The role of fluid biomarkers in patient care is a ...

    Authors: Pedro Rosa-Neto, Ging-Yuek Robin Hsiung and Mario Masellis

    Citation: Alzheimer's Research & Therapy 2013 5(Suppl 1):S8

    Content type: Review

    Published on:

    This article is part of a Supplement: Volume 5 Supplement 1

  39. Recently published guidelines suggest that the most opportune time to treat individuals with Alzheimer’s disease is during the preclinical phase of the disease. This is a phase when individuals are defined as ...

    Authors: Dorene M Rentz, Mario A Parra Rodriguez, Rebecca Amariglio, Yaakov Stern, Reisa Sperling and Steven Ferris

    Citation: Alzheimer's Research & Therapy 2013 5:58

    Content type: Review

    Published on:

  40. The clinical features of Alzheimer’s disease (AD) overlap with a number of other dementias and conclusive diagnosis is only achieved at autopsy. Accurate in-life diagnosis requires finding biomarkers suitable ...

    Authors: Noemí Esteras, Carolina Alquézar, Ana de la Encarnación, Alberto Villarejo, Félix Bermejo-Pareja and Ángeles Martín-Requero

    Citation: Alzheimer's Research & Therapy 2013 5:55

    Content type: Research

    Published on:

  41. Autophagy serves as the sole catabolic mechanism for degrading organelles and protein aggregates. Increasing evidence implicates autophagic dysfunction in Alzheimer’s disease (AD) and other neurodegenerative d...

    Authors: Miranda E Orr and Salvatore Oddo

    Citation: Alzheimer's Research & Therapy 2013 5:53

    Content type: Review

    Published on:

  42. The aim of this study was to explore the predictors of decline in walking ability in patients with Alzheimer’s disease (AD).

    Authors: Yves Rolland, Christelle Cantet, Philipede Souto Barreto, Matteo Cesari, Gabor Abellan van Kan and Bruno Vellas

    Citation: Alzheimer's Research & Therapy 2013 5:52

    Content type: Research

    Published on: